Publisher： Cognizant Communication Corporation
Founded in： 1985
Total resources： 2
E-ISSN： 1460-2148
ISSN： 1460-2148
Subject： R9 Pharmacy
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Anti-Cancer Drug Design
Menu
Synthesis and anticancer activity of nordihydroguaiaretic acid (NDGA) and analogues
By McDonald R.W., Bunjobpon1 W., Liu T., Fessler1 S., Pardo1 O.E., Freer I.K.A., Glaser1 M., Seckl1 M.J., Robins D.J. in (2001)
Anti-Cancer Drug Design , Vol. 16, Iss. 6, 2001-12 , pp.
Access to resources
Recommend
Cyclohexylamino-demethoxy-hypocrellin B and photodynamic therapy decreases human cancer in vitro
By Xu S., Chen S., Zhang M., Shen T., Liu1 Z., Zhao1 Y., Wu1 Y. in (2001)
Anti-Cancer Drug Design , Vol. 16, Iss. 6, 2001-12 , pp.By Bridewell D.J.A., Finlay G.J., Baguley B.C. in (2001)
Anti-Cancer Drug Design , Vol. 16, Iss. 6, 2001-12 , pp.By Rothenborg-Jensen1 L., Hansen4 H.F., Wessel1 I., Nitiss3 J.L., Schmidt24 G., Jensen2 P.B., Sehested1 M., Jensen12 L.H. in (2001)
Anti-Cancer Drug Design , Vol. 16, Iss. 6, 2001-12 , pp.Photokilling of cultured tumour cells by the porphyrin derivative CF3
By Villanueva A., Durantini1 E.N., Stockert J.C., Rello S., Vidania2 R., Cañete M., Juarranz A., Arranz R., Rivarola3 V. in (2001)
Anti-Cancer Drug Design , Vol. 16, Iss. 6, 2001-12 , pp.The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?
By McCluskey A., Ackland1 S.P., Gardiner E., Walkom C.C., Sakoff1 J.A. in (2001)
Anti-Cancer Drug Design , Vol. 16, Iss. 6, 2001-12 , pp.By Dodds12 H.M., Hanrahan1 J., Rivory12 L.P. in (2001)
Anti-Cancer Drug Design , Vol. 16, Iss. 4, 2001-08 , pp.Reversal of P-glycoprotein associated multidrug resistance by new isoprenoid derivatives
By Hayashi1 M., Koike2 K., Rho14 M-C., Kuwano3 M., Kishiye2 T., Komiyama1 K. in (2001)
Anti-Cancer Drug Design , Vol. 16, Iss. 4, 2001-08 , pp.
Previous
Next